A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer

  • Authors:
    • Susumu Adachi
    • Toshitada Ogasawara
    • Kimihiko Ito
    • Masayasu Koyama
    • Tadayoshi Nagano
    • Akira Suzuki
    • Toshio Yamada
    • Yoshinori Nakata
    • Mitsuru Ozawa
  • View Affiliations

  • Published online on: March 1, 2001     https://doi.org/10.3892/or.8.2.285
  • Pages: 285-288
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Combination chemotherapy with paclitaxel and platinum is the most effective regimen for advanced ovarian cancer. Second-line chemotherapy with paclitaxel (135 mg/m2, 24 h) and carboplatin (AUC 5-6) is also effective for patients who relapse on the same regimen after 6 months or more. However, it has been shown that the same efficacy and less myelosuppression can be achieved with a 3-h infusion of paclitaxel (135 mg/m2), and that dose intensification of carboplatin to an AUC values larger than 4-6 is meaningless. Therefore, we decided to conduct a pilot study of paclitaxel (135 mg/m2, 3 h) and carboplatin (AUC 4-5) for ovarian cancer patients who had relapsed or were resistant to a platinum-containing regimen without paclitaxel. Eligibility criteria included patients with relapsed or resistant ovarian cancer (no specified duration from prior therapy), age 16-75 years, with performance status 0-2, and adequate bone marrow, renal, and hepatic function. Paclitaxel was administered at a fixed dose of 135 mg/m2 followed by one of two carboplatin doses (AUC 4 or 5). Specific doses were alternated between individual patients by the order in which they entered the study. Treatment was repeated every 3 weeks, and more than 4 cycles were administered. A total of 11 patients were enrolled. Carboplatin was administered to 6 patients at an AUC of 4 and to 5 patients at an AUC of 5. The age of patients ranged from 18 to 65 years (median: 54). Other patient data (number of patients): serous (8), non serous (3), patients with measurable disease (9), assessable/CA 125 (3), study drug administration less than 6 months after prior therapy (5), study drug administration 6 months or more after prior therapy (6). Response was defined by CT and CA 125 level. CR was observed in 25% (2/8), PR in 38% (3/8), NC in 25% (2/8), and PD in 13% (1/8) of the patients. The response rate with assessable patients was 100% (3/3), and the overall response rate was 73% (8/11). Two patients with grade 1 tachycardia and grade 4 thrombocytopenia, respectively, refused further treatment after 2 cycles. No other patients experienced grade 4 hematologic toxicity or grade 3 non-hematologic toxicity. The median survival duration after paclitaxel and carboplatin therapy was 21+ months (6-26+ months). This regimen is easy to manage in heavily pretreated patients and seems to have good efficacy. To further assess the efficacy, a phase II study is needed.

Related Articles

Journal Cover

March-April 2001
Volume 8 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y and Ozawa M: A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Oncol Rep 8: 285-288, 2001
APA
Adachi, S., Ogasawara, T., Ito, K., Koyama, M., Nagano, T., Suzuki, A. ... Ozawa, M. (2001). A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer. Oncology Reports, 8, 285-288. https://doi.org/10.3892/or.8.2.285
MLA
Adachi, S., Ogasawara, T., Ito, K., Koyama, M., Nagano, T., Suzuki, A., Yamada, T., Nakata, Y., Ozawa, M."A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer". Oncology Reports 8.2 (2001): 285-288.
Chicago
Adachi, S., Ogasawara, T., Ito, K., Koyama, M., Nagano, T., Suzuki, A., Yamada, T., Nakata, Y., Ozawa, M."A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer". Oncology Reports 8, no. 2 (2001): 285-288. https://doi.org/10.3892/or.8.2.285